Despite a global prevalence of 10.6 million people, currently available therapies are ineffective in slowing progression and focus on managing symptoms, largely via acetyl cholinesterase (AChE ...

In general, clinical trials have demonstrated that the AChE inhibitors do offer modest symptomatic benefits to mild to moderate AD patients in the short term (6-12 months, and perhaps up to two ...